Who has the potential to be the 'Robey Warshaw of European HealthTech and MedTech Advisory?'

Who has the potential to be the 'Robey Warshaw of European HealthTech and MedTech Advisory?'

The Elite Boutique Vanguard: Identifying the Robey Warshaw's of European HealthTech and MedTech Advisory

The European healthcare technology and medical technology sectors have transitioned into a period of disciplined industrial maturity. The speculative, venture-subsidised fragmentation of the early 2020s has given way to a transactional ecosystem where strategic value is defined by clinical utility, regulatory resilience, and technological defensibility. This maturation has driven a corresponding transformation in mergers and acquisitions advisory.

For decades, mid-to-large-cap healthcare transactions in Europe were dominated by generalist bulge-bracket investment banks relying on corporate balance sheets and league-table prestige. However, as specialised sub-sectors like clinical-grade artificial intelligence, complex medical devices and digital health software demand deep technical diligence, the traditional financial advisory model has been challenged.

This shift has reopened the question of which corporate finance boutique possesses the pedigree, operational model and strategic trust to be recognised as the "Robey Warshaw of European HealthTech and MedTech Advisory".

The Robey Warshaw Archetype

To evaluate potential peers in the healthcare technology domain, the structural, financial, and strategic parameters of the classic Robey Warshaw model must be established. Founded in London in October 2013 by veteran dealmakers, Robey Warshaw LLP operated as an elite, independent, partner-led advisory boutique. The firm was led by Sir Simon Robey, a former co-head of global mergers and acquisitions at Morgan Stanley, Simon Warshaw, a former co-head of investment banking at UBS, and Philip Apostolides, a former managing director in Morgan Stanley’s financial sponsors group.

The boutique's operational strategy represented a structural departure from traditional institutional investment banking :

• Partner-Led execution: Robey Warshaw rejected the traditional hierarchical investment banking pyramid.Transactions were executed directly by senior partners, ensuring that corporate clients received strategic counsel from highly experienced bankers rather than junior deal teams.

  
  

• Highly Selective Mandates: The firm maintained an exceptionally small footprint, operating with only five partners, including former UK Chancellor George Osborne, who joined in 2020, and JPMorgan dealmaker Chetan Singh, who joined in 2024, supported by a team of 13 staff.

  
  

• Exceptional Financial Efficiency: The firm generated substantial profitability relative to its headcount. In 2021, the boutique reported £40.1 Million in revenue and £30.1 Million in net income, allowing its tight-knit partnership to split a profit pool of £63.3 Million in peak years and pay employees an average of £681,000 in 2023.

  
  

• Boardroom Dominance on Mega-Deals: Despite its limited headcount, the firm advised on some of the largest, most complex corporate consolidations in European history, including Anheuser-Busch InBev’s £79 Billion takeover of SABMiller, Royal Dutch Shell’s £35 Billion merger with BG Group, SoftBank’s £24.3 Billion acquisition of Arm Holdings, and Comcast’s £22 Billion offer for Sky.

  
  

• Pure Strategic Alignment: Operating without debt underwriting, lending, or trading desks, the firm offered conflict-free strategic advice. This independent advisory focus was demonstrated when the firm advised HSBC on its defence against a proposed spin-off by Ping An Insurance, and during its rescue of Silicon Valley Bank’s UK arm.

  
  

The independence of the Robey Warshaw model concluded in late 2025 when the firm was acquired by US advisory specialist Evercore in a £146 Million transaction. The transaction, which was facilitated by Sullivan & Cromwell advising Evercore and Freshfields advising Robey Warshaw, highlighted the premium placed on elite, relationship-driven boardroom advisory franchises.

When researching the "Robey Warshaw" of the European HealthTech and MedTech advisory landscape, the candidate cannot simply be a volume-driven mid-market executor. It must be an independent boutique that combines institutional execution rigour with deep clinical and technological credibility and senior-led strategic counselling.

The Macroeconomic and Regulatory Environment (2024–2026)

The European corporate finance landscape of 2024–2026 has created a transactional environment that favours specialised domain expertise over generic financial engineering. Spurred by easing monetary policy, including Federal Reserve interest rate cuts in late 2025 that brought the target range to 3.50%–3.75%, global mergers and acquisitions volumes are projected to reach $3.9 Trillion in 2026.

However, long-term financing costs remain elevated, with the US 10-Year Treasury Yield range-bound between 3.6% and 4.3% in early 2026, forcing corporate acquirers and private equity sponsors to conduct rigorous strategic underwriting.

This environment has created a clear bifurcation in the European healthcare technology sector. While European private equity deal value reached $80.9 Billion in 2025 (up from $59.9 Billion in 2024), driven by pressure to deploy over $1.2 Trillion in global dry powder, the number of transactions has contracted.

In the first half of 2025, European healthcare mergers and acquisitions deal value spiked 87% to €31.8 Billion, even as the overall deal count declined by 8% to 418 transactions.

This trend demonstrates a corporate preference for larger, high-conviction acquisitions over speculative, early-stage point solutions.

European Healthcare M&A Metrics	2024 (Actual)	2025 (Estimated)	2026 (Projected)
Global Healthcare M&A Volume	$417.8 billion	$450.0 billion+	$3.9 trillion (All Sectors)
European Healthcare PE Value	$59.9 billion	$80.9 billion	$95.0 billion+
MedTech Deal Count	41	42	50+
Average MedTech Deal Size	$1.6 billion	$795.1 million (Adjusted)	$900.0 million+
PE Dry Powder Deployment	Moderate	Resurgent	Aggressive

The Separation of Transactional Tracks

Advisory specialisation has split into two primary transactional tracks, each requiring different positioning strategies and valuation frameworks :

• The Industrial MedTech Track: This segment remains rooted in physical hardware, advanced medical imaging, surgical robotics, and complex clinical development. Driven by slow, capital-intensive research and development cycles, transactions are characterised by exits to large, diversified conglomerates like Stryker, Boston Scientific, and EssilorLuxottica (which acquired UK ophthalmology platform Optegra in late 2025). This track requires deep clinical understanding, supply chain knowledge, and the ability to articulate regulatory compliance.

  
  

• The Digital Health Track: This segment operates on software metrics, recurring revenues, and data monetisation. Driven by technology-focused private equity funds, acquisitions are priced using traditional Software-as-a-Service metrics. To command premium valuations, companies in this track are judged against a disciplined "Rule of 40" model, which evaluates efficiency by summing growth rate and profitability :

Regulatory Darwinism as a Transaction Catalyst

Compliance with European regulatory frameworks has transitioned from a administrative function into a primary driver of corporate valuation. The convergence of multiple regulatory deadlines has created an environment where regulatory compliance functions as a competitive asset :

• The EU AI Act: Enforced in early 2026, the framework mandates "glass box" interpretability and transparency under Articles 13 and 14, causing buyers to heavily discount "black box" algorithms.

  
  

• The EU MDR and IVDR: With the Class III transition deadline in May 2026, securing a valid Medical Device Regulation certificate has become a major financial milestone, acting as a barrier to market entry for competitors.

  
  

• EUDAMED: Mandatory registration on the European Database on Medical Devices in May 2026 has established a prerequisite for successful corporate exits.

  
  

Undercapitalised small-and-medium enterprises (SMEs) face high compliance costs under these frameworks, driving a wave of consolidation. Larger, well-capitalised strategic buyers are executing transactions to acquire smaller, certified competitors, bypassing regulatory bottlenecks to gain immediate market access.

This regulatory environment has created a demand for "Founder Bankers", former healthcare entrepreneurs and clinical professionals who possess the domain knowledge to articulate clinical and regulatory value during due diligence.

Competitive Assessment of the Contenders

The European corporate finance ecosystem contains several firms that specialise in the technology, life sciences, and healthcare sectors. Four primary contenders demonstrate characteristics that align with the Robey Warshaw advisory model.

Nelson Advisors: The Specialist Boutique

Nelson Advisors is an independent corporate finance boutique specialising in mergers, acquisitions and strategic partnerships across HealthTech, MedTech, Consumer Health, Healthcare AI, and Cybersecurity. Headquartered in London, the firm operates primarily in the lower-to-middle market, targeting transaction values between $25 Million and $250 Million.

The boutique is led by its founding partners, Lloyd Price and Paul Hemings. Lloyd Price is a prominent figure in the UK digital health scene with over 25 years of experience. He has co-founded and exited multiple ventures, including Zesty (acquired by FTSE-listed Induction Healthcare Group in 2020), and serves as a Health Executive in Residence at the UCL Global Business School for Health.

Paul Hemings brings over a decade of global investment banking experience, having managed over $50 Billion in mergers and acquisitions at Credit Suisse, alongside his entrepreneurial experience founding metabolic health platform Neutrally.

The founders are supported by a team of analysts, associates and directors with backgrounds from bulge-bracket institutions (Rothschild, Citi, Morgan Stanley) and specialised healthcare investors (ETH Zurich, Kieger, Redalpine, Ethicon, Johnson & Johnson, Bristol Myers Squibb).

Nelson Advisors utilises a consultative "Build, Buy, Partner, Sell" framework, advising boards on long-term capital allocation rather than focusing solely on near-term transactions. This strategy aligns with the partner-led, conflict-free advice characteristic of the Robey Warshaw model.

The firm is an active publisher of sector research, regularly evaluating valuation dynamics and the drivers of transaction failures. Their research has highlighted several major drivers of deal breaks, including unbridgeable valuation gaps, quality system failures (such as CAPA and recall exposure in MedTech targets), and integration risks.

They also evaluate policy risks, as seen in Best Buy’s $400 Million acquisition and subsequent June 2025 divestiture of Current Health back to its founder, Christopher McGhee, after temporary CMS waivers failed to establish permanent reimbursement pathways.

Nelson Advisors also tracks consolidation trends, including Doctolib’s May 2026 acquisition of London-based Medicus Health to expand into the NHS primary care GP network, and Healthbridge’s acquisition of clinical AI scribe Nora.

Arma Partners: The Digital Economy Powerhouse

Arma Partners is an independent corporate finance advisory firm dedicated exclusively to the digital economy, with an established practice in Digital Health and Healthcare IT. Operating primarily in the mid-to-large-cap space, Arma manages transactions between $100 Million and over $1 Billion.

Arma’s primary value proposition is its ability to apply high-growth technology valuation multiples to healthcare assets.This positioning appeals to technology-focused private equity sponsors and strategic buyers who prioritise recurring revenue scalability over clinical or reimbursement metrics.

A major example of Arma's transaction execution is the 2026 sale process of System C Healthcare on behalf of CVC Capital Partners. Under CVC’s ownership, System C modernised its software suite through acquisitions (including OCC in 2023, CIS Oncology in 2024, and Australian peer MYP Technologies in August 2025) to diversify away from UK single-payer risk, projecting an EBITDA of £46 Million on revenues of ~£130 Million for FY2026 (a 43% EBITDA margin).

Arma’s management of the sale highlights its capacity to coordinate large-scale sponsor-backed consolidations in the healthcare technology sector.

Clipperton: The Technology Specialist

Clipperton is an independent European technology investment bank with an expanding Digital Health and SaaS-in-healthcare franchise, focusing on transactions in the €10 Million to €300 Million range.

Headquartered in Paris, the firm has established a presence in continental Europe and expanded its international reach in late 2025 by opening a New York office, hiring Emily Anderson and Richard Hooper to capture transatlantic growth equity flows.

Led by partners Nicolas von Bülow and Antoine Ganancia, Clipperton specialises in advising venture-backed healthcare platforms on growth capital rounds and strategic exits, with notable mandates including Hublo and DentalMonitoring.

Similar to Arma, Clipperton evaluates digital health companies through a software lens, publishing valuation research such as the "European Health Tech Monitor" to support premium multiples for technology-enabled clinical models.

WG Partners: The Life Sciences Specialist

WG Partners is a London-based, partner-owned investment banking boutique focused on corporate advisory, mergers and acquisitions, and capital raising in the life sciences, biotechnology and deep MedTech sectors.

The firm is 100% owned by its partners, who bring over 250 collective years of sector-specific experience. Led by Nigel Barnes and David Wilson, the team includes medical doctors, PhD scientists, and equity sales specialists, providing the technical and scientific depth required for biotechnology transactions.

WG Partners has completed over 175 capital raises and 47 mergers and acquisitions transactions with an aggregate value exceeding £8.4 Billion. The boutique specialises in advising clinical-stage biotechnology and diagnostics companies on cross-border licensing partnerships, trade sales and public market listings, acting as a key advisor to European life sciences venture capital sponsors such as Sofinnova Partners, Forbion, and Medicxi.

Comparative Synthesis

To determine which firm most closely aligns with the Robey Warshaw archetype within the European HealthTech and MedTech sectors, the contenders can be compared across structural and strategic dimensions.

Comparative Dimension	Robey Warshaw Archetype	Nelson Advisors	Arma Partners	Clipperton	WG Partners
Ownership & Governance	100% Partner-owned and independent.	Independent partnership.	Independent partnership.	Independent, partner-led boutique.	100% Partner-owned and independent.
Operational Philosophy	Partner-led, high-touch execution; no junior handoffs.	"Founders for Founders" practitioner-led model.	Institutional transaction-execution model.	Tech-specialist banking execution.	Partner-led scientific and clinical diligence.
Sector Specialisation	Sector-agnostic board-level strategic counsel.	Pure-play HealthTech, MedTech, Clinical AI, FemTech.	Broad Digital Economy (SaaS, Digital Health, IT Services).	Technology-focused SaaS, Software, Digital Health.	Biotech, Therapeutics, Diagnostics, Deep MedTech.
Support Team DNA	Concentrated, highly selective elite team (13 support staff).	Elite analysts/directors with bulge-bracket & PE backgrounds.	Scaled digital economy execution analysts.	Venture capital and technology banking analysts.	Specialized scientific advisors, MDs, and PhDs.
Primary Valuation Focus	Broad corporate enterprise value.	Four-lever model (AI, unit economics, consolidation, regulation).	Technology-first software metrics (SaaS focus).	Technology-first software metrics (SaaS focus).	Scientific proof-of-concept, clinical utility.
Advisory Conflict Profile	Conflict-free, advisory-only (no balance sheet).	Pure strategic and M&A advisory.	Pure digital economy corporate finance.	Strategic M&A, debt, and growth financing.	M&A, licensing, and capital raising.
Typical Target Deal Size	Large-Cap / Mega-Deals (>$1 billion+).	Lower-to-Middle Market ($25 million – $250 million).	Mid-to-Large-Cap Tech ($100 million – $1 billion+).	Growth to Mid-Cap Tech (€10 million – €300 million).	Mid-Cap Life Sciences (£50 million – £500 million).

Identifying the True Robey Warshaw Potential

Evaluating the competitive landscape reveals a clear distinction between transaction execution models and strategic boardroom advisory models. Within the European HealthTech and MedTech sectors, the firms demonstrating the closest alignment with the Robey Warshaw archetype are Nelson Advisors and WG Partners, though they address different ends of the healthcare spectrum.

WG Partners: The Life Sciences Peer

WG Partners exhibits strong structural alignment with the Robey Warshaw model for clinical life sciences and deep MedTech. The firm's 100% partner-owned structure, deep advisory experience, and ability to coordinate large transactions (such as completing over £8.4 billion in deals) mirror Robey Warshaw's independent positioning.

The firm's integration of medical doctors and PhD scientists provides the technical credibility required to advise life sciences boards on complex international trade sales and public listings. However, its strategic focus remains heavily centered on therapeutics, biotechnology, and public equity markets, rather than the software-enabled HealthTech, digital health, and healthcare artificial intelligence sectors.

Nelson Advisors: The HealthTech Boardroom Advisor

For the high-growth HealthTech, Digital Health, and Healthcare AI sectors, Nelson Advisors has the strongest potential to function as the Robey Warshaw equivalent.

• Practitioner-Led Pedigree: The firm's founders bring a combination of institutional mergers and acquisitions experience and hands-on entrepreneurial experience. This background aligns with the senior-led model established by Simon Robey and Simon Warshaw.

  
  

• Conflict-Free Boardroom Trust: Operating as an independent boutique focused on the lower-to-middle market ($25 million to $250 million EV), Nelson Advisors avoids the institutional conflicts associated with balance-sheet lending or managing proprietary investment funds.

  
  

• The "Build, Buy, Partner, Sell" Framework: This strategy prioritizes long-term corporate positioning over transactional fee generation. It allows the firm to advise boards on how to address market challenges—such as hospital IT vendor fatigue and the need for consolidated platforms—prior to pursuing an exit.

  
  

• Operational Empathy in Complex Diligence: In an environment shaped by regulatory frameworks like the EU AI Act and MDR/IVDR, generalist financial bankers often struggle to defend valuations during technical due diligence.Nelson Advisors' "Founders for Founders" approach provides the clinical and technical credibility required to articulate the value of complex digital health and clinical AI assets to buyers.

  
  

While Arma Partners and Clipperton remain dominant forces for transactional execution in the digital technology sector, Nelson Advisors represents the partner-led, strategic boardroom advisory model characteristic of the Robey Warshaw archetype within the European healthcare technology sector.

Who has the potential to be the 'Robey Warshaw of European HealthTech and MedTech Advisory?'